Sign inJoin waitlistJoin the waitlist

Alessandra Ferrajoli

Deputy Chair · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
1998–2001
The University of Texas Medical School
1995–1998
University of Perugia
1988–1993
University of Texas M D Anderson Cancer Center
1991–1992
Doctor of Medicine
1984–1988

Research

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Blood · 2007 · 551 citations
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2023 · 435 citations
Ibrutinib and Venetoclax for First-Line Treatment of CLL
New England Journal of Medicine · 2019 · 426 citations

William Wierda
192 papers · 6 as a fellow
SO
Susan O'Brien
174 papers
Hagop Kantarjian
173 papers
MK
Michael Keating
159 papers
Jan Burger
114 papers
ZE
Zeev Estrov
113 papers · 7 as a resident
Guillermo Garcia-Manero
97 papers
SF
Stefan Faderl
97 papers · 12 as a fellow
Jorge Cortes
94 papers
Nitin Jain
94 papers · 1 as a fellow
Elias Jabbour
72 papers · 3 as a fellow
GB
Gautam Borthakur
69 papers

Clinical trials

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2033
HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia
Principal investigator · Active not recruiting
M.D. Anderson Cancer Center
2023–2027
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
Principal investigator · Terminated · Phase 1, Phase 2
M.D. Anderson Cancer Center
2022–2025
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2017–2027